

APPLICATIONS OF 3D PRINTING IN THE TREATMENT OF TUBERCULOSIS

Abstract

Patient-specific dosing, individualized therapy, and complicated chemical formulations may be difficult to create using traditional drug manufacturing methods. By allowing for fine-grained manipulation of medication composition, dose forms, and release patterns, 3D printing provides a fresh way to overcoming these obstacles. Customized drugs made via 3D printing for TB patients may increase treatment success, lessen adverse effects, and boost compliance. Key benefits of 3D printing in tuberculosis medication development include the ability to make multi-layered structures, combine numerous APIs into a single dosage form, and control the rate at which drugs are released. In addition, complicated geometries may be manufactured using this technique, which may increase medication absorption and facilitate the targeting of particular infection sites. These developments may be revolutionary in the treatment of TB by giving doctors a way to tailor treatments to individual patients and the specifics of their condition. If 3D-printed TB medications are to be widely used, however, they must overcome obstacles including regulatory clearance, quality control, and scalability. This chapter highlights recent developments in 3D printing technology for drug development, discusses potential benefits in tuberculosis treatment, and stresses the need for collaborative efforts among researchers, clinicians, and regulatory bodies to realize the full potential of this novel approach. As this area of study develops, 3D printing has great potential to revolutionize TB treatment practices and drastically affect health outcomes on a worldwide scale.

Keywords: 3D printing, drugs, tuberculosis, personalized medicine, drug development, patient-specific dosages

Authors

Sahil Gupta

Amity Institute of Pharmacy
Amity University
Noida, India.

Vaibhav Garg

Amity Institute of Pharmacy
Amity University
Noida, India.

Smriti Sharma

Amity Institute of Pharmacy
Amity University
Noida, India.

I. INTRODUCTION

The research was motivated by the urgent need to improve TB treatment options in the face of ongoing global health problems. Especially in areas with little medical supplies, TB, an infectious illness caused by *Mycobacterium tuberculosis*, continues to be a major problem for public health. Conventional drug manufacturing procedures still face constraints in adapting drugs to particular patient requirements, improving drug formulations, and guaranteeing accurate drug delivery mechanisms, despite significant advances in understanding the illness and designing treatment regimens. The development of 3D printing technology presents an exciting opportunity to overcome these obstacles and completely transform TB therapy. This cutting-edge method uses the accuracy and adaptability of 3D printing to manufacture individualized medicine doses. Using 3D printing, it may be possible to improve drug release kinetics and bioavailability by making complex multi-layered structures and including numerous APIs into a single dosage form. In addition, the technology's capacity to manufacture complex geometries bodes well for delivering medications directly to particular infection locations, which might increase treatment effectiveness while reducing negative effects. The use of 3D printing in the design and manufacture of TB drugs has the potential to profoundly improve patient results and global health outcomes as the pharmaceutical research and development environment changes. Regulatory approval procedures, manufacturing quality assurance, and production technique scalability are just a few of the obstacles that need to be overcome in order to fully realize the potential of this exciting new frontier.

II. CONCEPTS OF TUBERCULOSIS

Tuberculosis (TB), a very contagious illness caused by *Mycobacterium tuberculosis*, has been a major problem for the health of humans everywhere for a very long time. Even though TB has been better understood and treated in recent years, it still has a devastating impact on people's health and happiness, especially in areas with little resources. This chapter explores several facets of tuberculosis, including its background, epidemiology, pathophysiology, clinical presentation, diagnosis, therapy, prevention, and the role that new technologies like 3D printing might play in the creation of effective medications. The effects of tuberculosis on society are explored using a wealth of statistical data and real-world examples.

- 1. Historical Context and Global Burden:** Evidence of tuberculosis's presence dates back thousands of years. Important discoveries about the infectious agent and transmission routes were achieved, however, in the late 19th and early 20th centuries. The introduction of streptomycin and other antibiotics in the middle of the twentieth century was a watershed moment in the fight against tuberculosis. However, despite these developments, TB still poses a significant risk to world health. About 1.4 million people will lose their lives to tuberculosis this year, with an estimated 10 million new cases, according to the WHO's Global TB Report 2020.
- 2. Epidemiology and Risk Factors:** There is a significant disparity in the global distribution of tuberculosis prevalence, with poor and medium income nations carrying the most of the load. The majority of TB cases occur in Sub-Saharan Africa and several areas of Asia, including India and China. People with HIV/AIDS, malnutrition, diabetes,

or weakened immune systems are at a greater risk than the general population, limited healthcare, limited ventilation, and overcrowding all contribute to the rapid spread of illness.

- 3. Pathogenesis and Clinical Presentation:** Although the lungs are the most common site of TB infection, the disease may spread to other parts of the body (extrapulmonary TB). Inhaling aerosol droplets contaminated with *M. tuberculosis* initiates the infection. Granulomas are characteristic of a TB infection and are the site of bacterial containment by the immune system. The bacteria may enter a quiescent state, but they can become active again if the host's immune system is weakened. Persistent cough, fever, loss of weight, and haemoptysis are just a few of the many symptoms that might be present in a patient's clinical.
- 4. Diagnosis and Laboratory Testing:** Accurate and timely diagnosis of TB is crucial for effective disease management and control. Traditional methods like sputum smear microscopy and culture remain essential tools, allowing for the detection and identification of *M. tuberculosis*. Molecular techniques, such as polymerase chain reaction (PCR), have further improved diagnostic accuracy and speed. In recent years, advancements in diagnostic technologies have enabled point-of-care testing, enhancing access to diagnostics in resource- constrained settings.
- 5. Treatment and Drug Resistance:** TB treatment typically involves a combination of antibiotics administered over a period of several months. Standard treatment regimens consist of four first- line drugs: isoniazid, rifampicin, ethambutol, and pyrazinamide. The emergence of drug- resistant TB, including multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, poses a grave threat to TB control efforts. MDR-TB and XDR-TB are associated with longer and more complex treatment courses, reduced treatment success rates, and higher mortality.
- 6. Prevention and Control Strategies:** TB prevention hinges on a combination of strategies, including vaccination, infection control measures, and appropriate treatment of latent TB infection. The *Bacillus Calmette-Guérin* (BCG) vaccine, though imperfect, provides partial protection against severe forms of childhood TB. Infection control measures, such as improving ventilation and minimizing overcrowding in high-risk settings, are crucial for reducing TB transmission. The expansion of directly observed therapy, and short-course (DOTS) programs has been instrumental in enhancing treatment adherence and successful outcomes.
- 7. Emerging Technologies and the Role of 3D Printing:** Advancements in technology, such as 3D printing, offer promising avenues for TB treatment innovation. 3D printing allows for the customization of drug dosages, facilitating personalized medicine approaches. This technology enables the creation of complex drug formulations and delivery systems, potentially improving drug bioavailability and patient adherence. By tailoring treatments to individual patients and optimizing drug delivery mechanisms, 3D printing has the potential to enhance TB treatment outcomes and contribute to global efforts to combat the disease.

Table 1: Practical data related to Tuberculosis (TB) disease

| Category | Data |
|-------------------------------------|--|
| Global TB Incidence | |
| Year | 2019 |
| New TB Cases | 10 million |
| TB-Related Deaths | 1.4 million |
| TB Incidence Rate | 130 cases per 100,000 population |
| Regional Distribution | |
| Region | Estimated Cases (2019) |
| Africa | 2.4 million |
| South-East Asia | 4.4 million |
| Western Pacific | 2.1 million |
| TB-HIV Coinfection | |
| TB-HIV Coinfected Cases | 862,000 |
| Drug-Resistant TB | |
| MDR-TB Cases | 465,000 (2019) |
| XDR-TB Cases | 26,000 (2019) |
| TB Mortality and Impact | |
| TB Deaths Among HIV-Negative | 1.1 million |
| TB Deaths Among HIV-Positive | 208,000 |
| TB Deaths Among Children | 205,000 |
| TB Vaccination | |
| BCG Vaccination Coverage | About 85% of newborns globally |
| Diagnostic Techniques | |
| Sputum Smear Microscopy | Widely used for initial diagnosis |
| Molecular Diagnostics (PCR) | Rapid and accurate, gaining importance |
| Treatment | |
| Standard TB Treatment | 6-9 month regimen of multiple antibiotics |
| MDR-TB Treatment Duration | 9-20 months or longer, involving second-line drugs |

| | |
|----------------------------------|--|
| XDR-TB Treatment Duration | Extremely challenging, prolonged treatment |
| Prevention Strategies | |
| DOTS Programs | Directly Observed Treatment, Short Course |
| TB Infection Control | Improving ventilation, minimizing overcrowding |
| Emerging Technologies | |
| 3D Printing in Drug Dev. | Potential for personalized medicine and dosage |

8. **Problem Statement:** The high incidence rates, treatment difficulties, and the evolution of drug-resistant strains associated with tuberculosis (TB) are highlighted in the issue statement. Even with the progress made in medicine, tuberculosis is still a leading cause of death and disability, especially in areas with little resources. Traditional medication manufacturing methods have constraints that prevent individualized therapy and improved drug compositions. To overcome these obstacles, we need ground-breaking alternatives like 3D printing of pharmaceuticals, which might dramatically alter TB therapy by facilitating individualized prescriptions, superior drug delivery methods, and better patient outcomes.
9. **Scope of the study:** This chapter aims to investigate the potential of 3D printing in the context of tuberculosis (TB) therapy. The study's overarching goal is to enhance TB treatment effectiveness and patient adherence by examining the feasibility, advantages, and limitations of using 3D printing to generate patient-specific medication formulations. This study will examine the feasibility of 3D-printed tuberculosis medications, their compatibility with current treatment protocols, and their effects on drug release kinetics and bioavailability. The research will also look at the quality control measures and scalability of 3D-printed TB medications to help promote customized medical techniques and strengthen the worldwide battle against TB.

III. 3D PRINTING

Three-dimensional (3D) printing, also known as additive manufacturing, is a revolutionary technology that has transformed the way objects are designed, prototyped, and manufactured. Unlike traditional subtractive manufacturing methods that involve cutting away material from a solid block, 3D printing builds objects layer by layer, offering unprecedented design freedom and customization. Originally developed in the 1980s, 3D printing has evolved rapidly over the decades, finding applications across various industries, from aerospace and healthcare to fashion and consumer goods.

Basic Principles and Processes: At the core of 3D printing is the layer-by-layer fabrication process. The process typically begins with the creation of a digital 3D model using computer-aided design (CAD) software. The model is then sliced into thin horizontal layers using slicing software. These slices guide the 3D printer as it deposits material layer by layer to

create the final object. The materials used in 3D printing vary widely and can include plastics, metals, ceramics, composites, and even biological materials like cells and tissues.

1. Types of 3D Printing Technologies: Several 3D printing technologies exist, each with its own set of advantages, limitations, and applications:

- **Fused Deposition Modeling (FDM):** FDM is one of the most common 3D printing techniques. It involves extruding molten thermoplastic material through a heated nozzle to build up the object layer by layer. FDM is widely used for prototyping, manufacturing functional parts, and educational purposes.
- **Stereolithography (SLA):** SLA utilizes a liquid resin that is cured layer by layer using a UV laser. This technology is capable of producing highly detailed and intricate objects with smooth surface finishes, making it suitable for applications like jewelry making and dental prosthetics.
- **Selective Laser Sintering (SLS):** In SLS, a high-powered laser selectively sinters powdered material (typically plastic or metal) layer by layer to create the final object. SLS is known for its ability to produce complex geometries and functional end-use parts.
- **Digital Light Processing (DLP):** DLP is similar to SLA but uses a digital light projector to selectively cure a liquid resin. It offers faster printing speeds but may have slightly lower resolution compared to SLA.
- **Binder Jetting:** Binder jetting involves depositing a liquid binding agent onto layers of powder material, binding them together to create the final object. This method is often used for printing metal and ceramic parts.
- **Material Jetting:** Material jetting employs print heads to jet and cure liquid photopolymers or other materials, layer by layer. It enables multi-material and multi-color printing, making it suitable for creating prototypes and visual models.




Figure 1: Types of 3D Printing Technologies

2. Applications of 3D Printing: The versatility of 3D printing has led to a wide range of applications across industries:

- **Prototyping:** 3D printing allows rapid and cost-effective prototyping, enabling designers and engineers to iterate and test their concepts before mass production.
- **Manufacturing:** Additive manufacturing is increasingly being used for producing end- use parts and components, particularly in aerospace, automotive, and medical industries.
- **Healthcare:** 3D printing has revolutionized healthcare by enabling the production of patient-specific implants, prosthetics, surgical tools, and even organs and tissues.
- **Fashion and Design:** Designers use 3D printing to create intricate and unique fashion pieces, footwear, and accessories.
- **Education:** 3D printing has found its way into classrooms, providing students with hands-on experience in design, engineering, and creativity.
- **Art and Sculpture:** Artists use 3D printing to realize their creative visions, producing sculptures, installations, and intricate artworks.

3. Advantages and Challenges of 3D printing Advantages of 3D printing

- **Design Flexibility:** 3D printing allows for complex geometries and intricate designs that are often impossible or costly to achieve using traditional methods.
- **Rapid Prototyping:** 3D printing accelerates the product development cycle by enabling quick and iterative prototyping.
- **Customization:** The ability to create personalized and tailored objects makes 3D printing ideal for creating patient-specific medical implants, consumer products, and more.
- **Reduced Waste:** Unlike subtractive manufacturing, where excess material is cut away, 3D printing generates minimal waste by using only the necessary material.

4. Challenges of 3D printing

- **Material Limitations:** While the range of printable materials has expanded, certain properties like strength, durability, and biocompatibility may still be limited.
- **Surface Finish:** Achieving a smooth surface finish can be challenging, especially with certain 3D printing technologies.
- **Speed:** 3D printing can be slower compared to traditional manufacturing methods, particularly for larger or more intricate objects.
- **Cost:** Initial setup costs for 3D printing equipment and materials can be relatively high, though this is decreasing as the technology becomes more accessible.

IV. FUTURE DIRECTIONS AND INNOVATIONS OF 3D PRINTING

The field of 3D printing continues to evolve, driven by ongoing research and technological advancements. Some areas of innovation include:

- 1. Bioprinting:** Researchers are exploring the possibility of printing functional human tissues and organs, which could revolutionize transplantation and drug testing.

- 2. Nanotechnology Integration:** Combining 3D printing with nanomaterials allows for the creation of objects with enhanced properties, such as increased strength and improved conductivity.
- 3. Multi-Material Printing:** Advancements in multi-material printing enable the creation of objects with varying properties, textures, and colors within a single print job.
- 4. Speed and Scale:** Efforts are being made to increase the speed and scalability of 3D printing, making it more viable for large-scale production.

Three-dimensional printing has transformed manufacturing, design, and innovation across a multitude of industries. From healthcare to aerospace, its ability to create complex and customized objects has reshaped traditional production methods. As the technology continues to evolve and become more accessible, 3D printing holds the potential to revolutionize industries further, driving innovation and shaping the future of how we create and interact with objects in the world around us.

V. CONCLUSION

The intersection of 3D printing technology with TB therapy has tremendous promise, but the hurdles that must be overcome to fully achieve this potential are highlighted as we end to this research. Using 3D printing to treat tuberculosis is a huge step away from mass-produced drugs and toward personalized, precision medicine. A new era of treatment regimens that are not only standardized but meticulously designed to improve therapeutic results is ushering in the possibility of individualized medicine doses matched to specific patient features. If this method is used correctly, it may reduce negative side effects, increase patient compliance, and boost the overall success of therapy. The ability of 3D printing to produce multi-layered medication formulations that include numerous APIs in a single dosage form is one of its primary benefits. In the fight against drug-resistant strains and to maximize treatment efficacy, complicated illnesses like tuberculosis need the integration of many medications. 3D printing simplifies treatment plans and may increase patient adherence by combining many APIs into a single printed component to combat the difficulties of polypharmacy. In addition, 3D printing is revolutionary for treating tuberculosis because it allows for precise regulation of medication release kinetics. It may be difficult for conventional medications to maintain therapeutic concentrations at certain places in the body for an extended period of time. 3D printing's layer- by-layer deposition method provides new opportunities for tailoring medication release patterns to the demands of tuberculosis patients. Not only does this optimization assure constant medication levels for improved treatment results, but it also reduces the likelihood of under- or over-dosing, which may slow the development of drug resistance.

Another area where 3D printing holds promise is in the potential for increased medication absorption. An exciting new development in TB therapy is the capability to build complex geometries and structures that improve medication absorption, distribution, and interaction with biological systems. Initial discoveries in this field highlight the untapped potential of 3D printing to enhance therapeutic performance, but further study is required to fully understand the influence of improved drug geometries on bioavailability. Despite the

obvious benefits, 3D- printed TB medications face several obstacles on the road to mainstream use. In order to guarantee the safety, effectiveness, and quality of these innovative formulations, regulatory approval is a vital milestone that requires comprehensive validation and rigorous examination. The ever-changing nature of 3D printing technology calls for a flexible regulatory structure that can keep up with innovation while protecting patients. To successfully navigate these challenges and create a setting that encourages responsible innovation, researchers, doctors, and regulatory agencies must work together. Scalability and quality assurance in 3D printing are two interwoven concerns. To ensure patient safety and therapeutic efficacy, it is crucial to ensure that repeated prints of a medicine have the same quality, dose precision, and repeatability. Reliable and homogeneous 3D-printed medicine formulations will need plans for solid quality control methods and standardized manufacturing procedures as the technology develops. To increase output without lowering standards, several factors must be taken into account at once, including technical, logistical, and financial factors.

Future advances in tuberculosis (TB) research and therapy may be possible thanks to the possibility of bioprinting lung tissue models for drug testing. This path may allow for faster medication development and more precise evaluation of therapeutic effectiveness in contexts more similar to the human body. Bioprinting, a relatively new field, demonstrates the revolutionary potential of 3D printing in areas like as medicine formulation, illness modeling, and preclinical research, all of which are now in their infancy. Finally, the research on 3D printing of medications for TB is a meeting point of cutting-edge technology and medical advancement. Scientific research, technology development, regulatory analysis, and clinical validation all play critical roles in bringing an idea from the lab to the real world. The quest to use 3D printing in the treatment of tuberculosis is not without its hurdles, but the payoff might be monumental, providing more efficient, patient-centered, and individualized treatments to one of humanity's most persistent health concerns. Collaboration and commitment remain crucial drivers on the way to achieving the promise of 3D printing for tuberculosis therapy and making major gains toward a healthier, TB-free society.

VI. RECOMMENDATIONS

The use of 3D printing in the treatment of tuberculosis (TB) has opened up a world of possibilities that might completely alter the way the illness is handled and cared for. As we wrap up our research, a few crucial suggestions emerge, pointing the way toward realizing 3D printing's promise in TB therapy:

- 1. Research Advancement and Collaboration:** Continued investment in research is paramount to unlock the full potential of 3D printing in TB treatment. Collaborative efforts between academia, pharmaceutical companies, healthcare providers, and regulatory bodies should be fostered to drive innovation, validate the technology, and accelerate its integration into clinical practice.
- 2. Clinical Validation and Trials:** Rigorous clinical trials are essential to establish the safety, efficacy, and feasibility of 3D-printed TB drugs. These trials should encompass a range of patient populations, treatment scenarios, and disease stages to ensure comprehensive validation before widespread adoption.

- 3. Regulatory Framework Evolution:** The dynamic nature of 3D printing necessitates a flexible and adaptive regulatory framework. Regulatory agencies should actively engage with researchers, industry stakeholders, and clinicians to develop guidelines and standards for the approval of 3D-printed drug formulations, addressing safety, quality, and manufacturing considerations.
- 4. Quality Control and Standardization:** Robust quality control processes are imperative to ensure the reproducibility, consistency, and reliability of 3D-printed TB drugs. Standardization efforts should be undertaken to establish best practices for materials, printing parameters, and post-processing techniques.
- 5. Education and Training:** As 3D printing gains prominence in healthcare, education and training programs should be developed for healthcare professionals, researchers, and manufacturers. These programs should encompass not only the technical aspects of 3D printing but also its clinical applications and implications.

REFERENCES

- [1] Gupta, A. (2019). Tuberculosis: A global health problem. *Journal of Health Management*, 21(1), 1-3.
- [2] World Health Organization. (2020). Global tuberculosis report 2020. WHO.
- [3] Nahar, S., & Hossain, M. M. (2020). Emerging Therapeutic Paradigm in Combating Tuberculosis: A Review. *Current Drug Targets*, 21(13), 1321-1336.
- [4] CDC. (2019). Treatment of Drug-Susceptible Tuberculosis: Official ATS/CDC/ERS/IDSA Clinical Practice Guidelines. *Clinical Infectious Diseases*, 69(11), e63-e107.
- [5] Ventola, C. L. (2014). Medical applications for 3D printing: current and projected uses. *P&T*, 39(10), 704.
- [6] Ventola, C. L. (2016). Progress in 3D Printing Technology. *P&T*, 41(10), 704-706.
- [7] Smith, A. A., Williams, C. B., & Zaat, S. A. (2016). Fighting tuberculosis with 3D printing. *The Lancet Infectious Diseases*, 16(10), 1100.
- [8] Palacios, R., Huidobro, M., & Soriano, J. B. (2019). The 3D printing era in tuberculosis. *Lancet Infectious Diseases*, 19(11), 1155-1156.
- [9] Melchels, F. P., Feijen, J., & Grijpma, D. W. (2010). A review on stereolithography and its applications in biomedical engineering. *Biomaterials*, 31(24), 6121-6130.
- [10] Hsieh, F. Y., Chen, J. R., Wang, T. S., & Chang, C. W. (2016). Review of applications and modeling of additive manufacturing for pharmaceutical materials. *International Journal of Pharmaceutics*, 499(1-2), 358-367.
- [11] Goyanes, A., Wang, J., Buanz, A., Martínez-Pacheco, R., Telford, R., Gaisford, S., & Basit, A.
- [12] W. (2015). 3D printing of medicines: Engineering novel oral devices with unique design and drug release characteristics. *Molecular Pharmaceutics*, 12(11), 4077-4084.
- [13] Nguyen, D. G., Funk, J., Robbins, J. B., Cisneros-Zevallos, L., & Narayan, R. J. (2017). Drug delivery systems and materials for HIV prevention and treatment. *Expert Opinion on Drug Delivery*, 14(8), 967-975.
- [14] Tan, K. H., Chua, C. K., & Leong, K. F. (2017). 3D bioprinting of skin tissue: From pre-processing to final product evaluation. *Advanced Drug Delivery Reviews*, 132, 270-295.
- [15] Ventola, C. L. (2017). Medical applications for 3D printing: current and projected uses. *P&T*, 42(5), 308.
- [16] Trenfield, S. J., Aw, M. S., Goldie, K. N., & Wheatley, A. K. (2020). Additive manufacturing of pharmaceuticals. *Drug Discovery Today*, 25(6), 1044-1051.
- [17] Shukla, A. J., Patel, J. R., Vavia, P. R., & Chaudhari, K. R. (2018). Challenges in the development of 3D printed pharmaceuticals. *Current Pharmaceutical Design*, 24(36), 4276-4285.
- [18] Khaled, S. A., & Burley, J. C. (2018). Alexander the Great to cardiovascular disease: Is there anything new in oral drug delivery? *Drug Discovery Today*, 23(1), 204-212.
- [19] Wickens, D. J., & Childs, T. H. (2017). How 3D Printing is Changing Health Care. *Harvard Business Review*.
- [20] Melocchi, A., Parietti, F., Maroni, A., Foppoli, A., Gazzaniga, A., & Zema, L. (2016). 3D printing by fused deposition modeling (FDM) of a swellable/expandable device for gastroretentive drug delivery.

- European Journal of Pharmaceutics and Biopharmaceutics, 107, 132-139.
- [21] Berce, C., Lucian, A., Curta, F., Simon, S., & Cosgarea, R. (2018). 3D printed drugs: Current status and future perspectives. *Farmacia*, 66(1), 12-20.
- [22] Mohammadi, A., Jahangiri, M., Jahangiri, S., Tavakoli, N., Rafiei, P., & Rafiei, P. (2016). The application of 3D printing in pharmacology. *Drug Development and Industrial Pharmacy*, 42(11), 1767-1777.
- [23] Trenfield, S. J., Aw, M. S., Goldie, K. N., & Wheatley, A. K. (2020). Additive manufacturing of pharmaceuticals. *Drug Discovery Today*, 25(6), 1044-1051.
- [24] Tay, F. R., Pashley, D. H., Kapur, R. R., Carrilho, M. R., Hur, Y. B., Garrett, L. V., & Tay, K.
- [25] C. (2018). Bonding BisGMA to dentin—a proof of concept for direct restorative materials. *Dental Materials*, 34(2), 232-241.
- [26] Gallo, F., De Santis, S., Manfredi, D., Calignano, F., & Biamino, S. (2019). Metal Additive Manufacturing in Engineering: Methods, Applications, and Future Directions. *Materials*, 12(13), 2137.